Skip to content
Screener

BridgeBio Pharma BBIO Non-Controlling Interests

Non-Controlling Interests at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$2.95B-6.4%
Arrowhead Research logo
Arrowhead ResearchARWR
-$15.06M-1,766%

Other financials

Income statement

See full
Revenue$243.7M+120%
Gross profit$228.6M+114%
Operating income-$107.1M+20.3%
Net income-$155.9M+15.2%
EPS (diluted)-$0.78+17.9%

Balance sheet

See full
Cash & equivalents$680.0M-9.5%
Total debt$3.3B+36,912%
Total equity-$2.5B-40.7%
Total assets$1.2B+12.7%

Cash flow

See full
Operating cash flow-$71.1M+11.9%
CapEx$443.0K-25.4%
Free cash flow-$71.5M+12.0%

Valuation

See full
Market cap$16.55B+79.4%
Enterprise value$19.13B+126%
P/S23.2×-15.9×

Profitability

See full
Gross margin94.4%-1.8pp
Operating margin-69.8%-29.9pp
Net margin-98.5%-40.7pp
FCF margin-61.1%-26.8pp

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.2×-4.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001743881-26-000027
Line itemJune 30,2026December 31,2025
Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025(533,279)(323,276)
Additional paid-in capital2,155,3182,057,646
Accumulated other comprehensive income (loss)(7)12
Accumulated deficit(4,137,453)(3,821,194)
Total BridgeBio stockholders’ deficit(2,515,215)(2,086,610)
Noncontrolling interests10,34010,599
Total stockholders’ deficit(2,504,875)(2,076,011)
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit$1,217,299$936,025

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's non-controlling interests?
BridgeBio Pharma (BBIO) reported non-controlling interests of $10.34M in Q2 2026.
How has BridgeBio Pharma's non-controlling interests changed year-over-year?
BridgeBio Pharma's non-controlling interests increased by 4.6% year-over-year, from $9.89M to $10.34M.
What is the long-term trend for BridgeBio Pharma's non-controlling interests?
Over 5 years (2020 to 2025), BridgeBio Pharma's non-controlling interests has grown at a -26.2% compound annual growth rate (CAGR), from $48.35M to $10.6M.
What does non-controlling interests mean?
Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.

Ask your AI about BridgeBio Pharma's non-controlling interests.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude